Bacterial or Non-Bacterial Infection?
FebriDx® aids in the differentiation between bacterial infection and non-bacterial etiology.
Acute respiratory infections, causing symptoms such as common cold, sore throat, cough, congestion and runny nose, are the most common reason for seeking medical advice and antibiotic prescriptions.1-3 Differentiating between bacterial infection and non-bacterial etiology can be challenging due to an overlap in signs and symptoms of bacterial and non-bacterial infections.
The majority of acute respiratory infections are caused by viruses and do not require antibiotics, yet antibiotics are prescribed in up to 50% of cases.4 Antibiotic resistance continues to remain a major global health threat contributing to 2.8 million antibiotic-resistant illnesses and 35,000 deaths each year in the U.S.5
Acute respiratory infections, causing symptoms such as common cold, sore throat, cough, congestion and runny nose, are the most common reason for seeking medical advice and antibiotic prescriptions.1-3 Differentiating between bacterial infection and non-bacterial etiology can be challenging due to an overlap in signs and symptoms of bacterial and non-bacterial infections.
The majority of acute respiratory infections are caused by viruses and do not require antibiotics, yet antibiotics are prescribed in up to 50% of cases.4 Antibiotic resistance continues to remain a major global health threat contributing to 2.8 million antibiotic-resistant illnesses and 35,000 deaths each year in the U.S.5
Introducing FebriDx® Point-of-Care Test Device
FebriDx® is a rapid point-of-care test that uses a fingerstick blood sample to aid in the differentiation between bacterial infection and non-bacterial etiology. FebriDx® is intended to be used in urgent and emergency care settings.
Knowing whether a patient has a bacterial infection has a direct impact on reducing unnecessary antibiotic prescriptions, limiting the spread of antibiotic-resistant bacteria, and helping providers know when to initiate treatment.
Knowing whether a patient has a bacterial infection has a direct impact on reducing unnecessary antibiotic prescriptions, limiting the spread of antibiotic-resistant bacteria, and helping providers know when to initiate treatment.
- Results after 10 minutes increases confidence in whether or not to prescribe an antibiotic.
- Highly sensitive/specific dual biomarker technology provides reliable differentiation of bacterial and non-bacterial infections.
- All-in-one, instrument-free test device means no expensive equipment and a fully portable solution.
Using FebriDx® during a patient visit can reduce diagnostic uncertainty and help guide appropriate patient management and reduce inappropriate antibiotics. Results are available after 10 minutes, allowing the clinician to provide a timely and targeted treatment plan during the initial visit.
Increase confidence in decision making
Confidently rule out a bacterial infection with 99% negative predictive value (NPV)6,7- Ensure bacterial infections are not overlooked
Increased confidence in patient diagnosis - Improve patient satisfaction
Support patient understanding of treatment plan with a tangible test result - Enable improved patient management
Actionable results after 10 minutes for use during a patient visit - Support antimicrobial stewardship
Reduce unnecessary antibiotic use6-9
- Harris AM, Hicks LA, Qaseem A. Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. Mar 15 2016;164(6):425-34. doi:10.7326/m15-1840.
- Centers for Disease Control and Prevention (CDC). National Ambulatory Medical Care Survey: 2019 National Summary Tables. https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2019-namcs-web-tables-508.pdf.
- Renati S, Linder JA. Necessity of office visits for acute respiratory infections in primary care. Fam Pract. 2016;33(3):312-317.
- Fleming-Dutra, K. E., Hersh, A. L., Shapiro, D. J., Bartoces, M., Enns, E. A., File, T. M., ... & Hicks, L. A. (2016). Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA. 315(17), 1864-1873.
- Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States. 2019. Accessed August 2023. https://stacks.cdc.gov/view/cdc/82532
- Shapiro NI, Self WH, Rosen J, et al. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. Ann Med. Aug 2018;50(5):420-429. doi:10.1080/07853890.2018.1474002
- Shapiro NI, Filbin MR, Hou PC, et al. Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient Setting. JAMA Network Open. 2022;5(10):e2234588-e2234588. doi:10.1001/jamanetworkopen.2022.34588
- Davidson M. FebriDx point-of-care testing to guide antibiotic therapy for acute respiratory tract infection in UK primary care: a retrospective outcome analysis. J Infect Dis Preve Med. 2017;5(3):165.
- Carlton HC, Savović J, Dawson S, Mitchelmore PJ, Elwenspoek MM. Novel point-of-care biomarker combination tests to differentiate acute bacterial from viral respiratory tract infections to guide antibiotic prescribing: A systematic review. Clin Microbiol Infect. 2021;
Contact us to learn more about FebriDx.
